Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL393366 | 0.99 | F10 (0.71) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1644697 | 0.94 | F10 (0.73) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1688728 | 0.93 | F10 (0.74) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL391730 | 0.92 | F10 (0.73) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8100116 | 0.92 | F10 (0.62) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL2190844 | 0.91 | F10 (0.61) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1645365 | 0.90 | F10 (0.71) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL391962 | 0.89 | F10 (0.70) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1644630 | 0.89 | F10 (0.70) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL388566 | 0.89 | F10 (0.70) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-8101601-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-8101601-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| EP-1987026-B1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2007093328-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | PLG, AADAC, DNPEP | F10 604/4885CYP1A2 386/4885CYP3A4 560/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | F10 604/4885CYP1A2 386/4885CYP3A4 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.